Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.63 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP12 | P39900 | 2/20 | 0.35 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.32 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.32 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uracil SCHEMBL8235 | 0.79 | — | — | |
| Uracil SCHEMBL11607890 | 0.79 | — | — | |
| Uracil SCHEMBL3798527 | 0.79 | CRBN (1.00) | CRBNMMP2TP53GAA | |
| Uracil SCHEMBL5089507 | 0.79 | — | — | |
| Uracil SCHEMBL29096415 | 0.78 | CRBN (0.77) | CRBNMMP2TP53 | |
| Uracil SCHEMBL710130 | 0.77 | — | — | |
| Uracil SCHEMBL18010636 | 0.77 | — | — | |
| Uracil SCHEMBL6703252 | 0.77 | — | — | |
| Uracil SCHEMBL21385227 | 0.77 | — | — | |
| Uracil SCHEMBL156275 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1305296-B9 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | US GOV HEALTH & HUMAN SERV (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-1305296-B1 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | US GOV HEALTH & HUMAN SERV (US) | 2009-09-09 | — | — | EP | disclosed |
| US-7009050-B2 | 5-Substituted pyrimidine derivatives of conformationally locked nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-03-07 | — | — | US | disclosed |
| US-20050282837-A1 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2005-12-22 | — | — | US | disclosed |
| EP-1305296-A2 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | The Government of the United States of America, as represented by the Secretary Department of Health and Human Services (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002008204-A2 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282837-A1 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | TYMP, DPYD, TYMS | CRBN 3492/4885MMP2 3715/4885TP53 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.